HealthQuest Capital led the funding, with participation from Aisling Capital and Polaris Partners.
The funds will be used to strategically operate and expand innovative medical device companies.
Led by Duke Rohlen, Doug Koo and Aftab Kherani, Ajax Health will seek innovative technologies in the medical device space and value-creating business models with potential for high-exit demand where returns can be realized within 48 months.
Core teams leading these companies should have a strategic combination of market, technical and execution experience.
The Ajax Health team will then integrate their experience to complement and support that of the medical device companies.
Ajax Health Chairman and CEO Rohlen has served in top executive roles and led successful exits at EPIX Therapeutics, Ajax Vascular, Spirox, CV Ingenuity and FoxHollow Technologies.
Rohlen is joined by Dr. Kherani, who serves as Ajax Health’s chief medical officer, and Koo, who is the company’s chief financial officer.